Abstract
Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Current Drug Therapy
Title:Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study
Volume: 8 Issue: 3
Author(s): Philippe Bareille, Ann Allen, Kelly Hardes and Alison Donald
Affiliation:
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Abstract: Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Export Options
About this article
Cite this article as:
Bareille Philippe, Allen Ann, Hardes Kelly and Donald Alison, Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113089990005
DOI https://dx.doi.org/10.2174/15748855113089990005 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Pathology Among Patients with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis
Current Diabetes Reviews SARS-CoV-2 Transmission Among Healthcare Workers in Iran: An Urgent Need for Early Identification and Management
Infectious Disorders - Drug Targets Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Computational Analysis of Interactions of Argadin with Chitotriosidase, Chitinase and Acidic Mammalian Chitinase: Hints for Specific Inhibitor Design
Letters in Drug Design & Discovery Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1
Current Medicinal Chemistry A Review of Recent Patents Concerning Therapy of Respiratory Diseases Using Gene Silencing by RNAi (RISC) and EGS (RNAse P)
Recent Patents on Inflammation & Allergy Drug Discovery Characterization of a Novel Polysaccharide-Iron(III) Complex and Its Anti-Anemia and Nonspecific Immune Regulating Activities
Mini-Reviews in Medicinal Chemistry Management of Certain Respiratory Disorders through Ayurveda: A Systematic Review of Clinical Studies Published in Ayurveda Journal
Current Traditional Medicine Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Cardiovascular Therapeutics Targets on the NO–sGC–cGMP Signaling Pathway: A Critical Overview
Current Drug Targets Nutritional Aspects Relating to the Developmental Origins of Health and Disease
Current Women`s Health Reviews Sleep and the Immune System
Current Immunology Reviews (Discontinued) Editorial [Hot Topic: Modulation and New Mediators in Inflammation Executive (Guest Editor: Frank A. Redegeld)]
Current Pharmaceutical Design Pro-inflammatory and Pro-apoptotic Role of IL-33 in the Human Acute Lung Injury (ALI) Development
Current Signal Transduction Therapy Factors Associated with Self-Reported Drug Allergies in a Large Chronic Spontaneous Urticaria Cohort
Current Drug Safety Anti-Allergic and Antioxidant Activity of 5-Hydroxy-3,6,7,3’,4’- Pentamethoxy Flavone Isolated from Leaves of Vitex negundo
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research
Current Medicinal Chemistry Hygiene Hypothesis and Occupational Asthma to Vegetable Textile Dusts: A Pilot Study
Current Respiratory Medicine Reviews Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry